{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:16:16Z","timestamp":1759936576305},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2014,8,7]],"date-time":"2014-08-07T00:00:00Z","timestamp":1407369600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1003769","type":"journal-article","created":{"date-parts":[[2014,8,7]],"date-time":"2014-08-07T18:04:23Z","timestamp":1407434663000},"page":"e1003769","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis"],"prefix":"10.1371","volume":"10","author":[{"given":"Jessica M.","family":"Conway","sequence":"first","affiliation":[]},{"given":"Alan S.","family":"Perelson","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2014,8,7]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.antiviral.2014.02.011","article-title":"Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?","volume":"105","author":"M Schneider","year":"2014","journal-title":"Antiviral Res"},{"key":"ref2","first-page":"321","article-title":"Treatment of chronic hepatitis C: current and future","volume":"369","author":"J Pawlotsky","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C dynamics <italic>in vivo<\/italic> and the antiviral efficacy of interferon-<italic>\u03b1<\/italic> therapy","volume":"282","author":"AU Neumann","year":"1998","journal-title":"Science"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nature03153","article-title":"Modelling how ribavirin improves interferon response rates in hepatitis C virus infection","volume":"432","author":"NM Dixit","year":"2004","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jtbi.2010.08.036","article-title":"Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics","volume":"267","author":"J Guedj","year":"2010","journal-title":"J Theor Biol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/hep.24272","article-title":"Second-phase hepatitis C virus RNA decline during telapravir-based therapy increases with drug effectiveness: implications for treatment initiation","volume":"53","author":"J Guedj","year":"2011","journal-title":"Hepatology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"30ra32","DOI":"10.1126\/scitranslmed.3000544","article-title":"Rapid emergence of protease inhibitor resistance in hepatitis C virus","volume":"2","author":"L Rong","year":"2010","journal-title":"Sci Transl Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2893.2007.00954.x","article-title":"Modelling hepatitis C virus kinetics during treatment with pegylated interferon alpha-2b: errors in the estimation of viral kinetic parameters","volume":"15","author":"E Shudo","year":"2008","journal-title":"J Viral Hepat"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2893.2008.00977.x","article-title":"Modelling the kinetics of hepatitis C virus RNA decline over 4 weeks of treatment with pegylated interferon alpha-2b","volume":"15","author":"E Shudo","year":"2008","journal-title":"J Viral Hepat"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/clpt.2010.35","article-title":"A comprehensive hepatitis C viral kinetic model explaining cure","volume":"87","author":"E Snoeck","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/135965350801300711","article-title":"A hepatitis C viral kinetic model that allows for time-varying drug effectiveness","volume":"13","author":"E Shudo","year":"2008","journal-title":"Antivir Ther"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1517\/17425250902787616","article-title":"Modeling HCV kinetics under therapy using PK and PD information","volume":"5","author":"E Shudo","year":"2009","journal-title":"Expert Opin Drug Met"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1055\/s-2003-41630","article-title":"Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b","volume":"23","author":"KA Powers","year":"2003","journal-title":"Semin Liver Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/hep.21136","article-title":"Pharmacodynamics of PEG-IFN alpha differentiate HIV\/HCV coinfected sustained virological responders from nonresponders","volume":"43","author":"AH Talal","year":"2006","journal-title":"Hepatology"},{"key":"ref15","unstructured":"Burnham KP, Anderson DR (2002) Model Selection and Multimodel Inference: A Practical Information-Theoretic Approach. New York: Springer, 2nd edition."},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/hep.24788","article-title":"Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)","volume":"55","author":"J Guedj","year":"2012","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3851\/IMP2733","article-title":"Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938","volume":"19","author":"J Guedj","year":"2014","journal-title":"Antivir Ther"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"29812","DOI":"10.1074\/jbc.M705274200","article-title":"Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2\u2032-Deoxy-2\u2032-fluoro-2\u2032-C-methylcytidine (PSI-6130) and identification of a novel active 5\u2032-triphosphate species","volume":"282","author":"H Ma","year":"2007","journal-title":"J Biol Chem"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Canini L, DebRoy S, Mari\u00f1o, Conway JM, Crespo G, <etal>et al<\/etal>.. (2014) Severity of liver disease affects hepatitis C virus kinetics in patients treated with intravenous silibinin monotherapy. Antivir Ther: In press.","DOI":"10.3851\/IMP2806"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/hep.24310","article-title":"Silibinin&apos;s mode of action against hepatitis C virus: a controversy yet to be resolved","volume":"54","author":"H Dahari","year":"2011","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jhep.2011.12.012","article-title":"Understanding silibinin&apos;s modes of action against HCV using viral kinetic modeling","volume":"56","author":"J Guedj","year":"2012","journal-title":"J Hepatol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/cpa.3160070404","article-title":"On the exponential solution of differential equations for a linear operator","volume":"VII","author":"W Magnus","year":"1954","journal-title":"Commun Pur Appl Math"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.physrep.2008.11.001","article-title":"The Magnus expansion and some of its applications","volume":"470","author":"S Blanes","year":"2009","journal-title":"Physical Reports"},{"key":"ref24","unstructured":"Spanier J, Oldham KB (1987) An Atlas of Functions. USA: Hemisphere Publishing Corporation."},{"key":"ref25","doi-asserted-by":"crossref","first-page":"e1002959","DOI":"10.1371\/journal.pcbi.1002959","article-title":"Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model","volume":"9","author":"L Rong","year":"2013","journal-title":"PLoS Comp Biol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1073\/pnas.1203110110","article-title":"Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life","volume":"110","author":"J Guedj","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref27","unstructured":"Edwards CH, Penney DE (1998) Calculus with Analytic Geometry. 5th edition. USA: Prentice-Hall Inc."},{"key":"ref28","first-page":"1866","article-title":"Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking","volume":"15","author":"J Blaising","year":"2013","journal-title":"Cell Microbiol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1137\/S0036144598335107","article-title":"Mathematical analysis of HIV-1: Dynamics <italic>in vivo<\/italic>","volume":"41","author":"AS Perelson","year":"1999","journal-title":"SIAM Rev"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nri700","article-title":"Modelling viral and immune system dynamics","volume":"5","author":"AS Perelson","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/hep.510290626","article-title":"Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy","volume":"29","author":"M Tsiang","year":"1999","journal-title":"Hepatology"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/jhep.2001.28509","article-title":"Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed","volume":"34","author":"SR Lewin","year":"2001","journal-title":"Hepatology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.22586","article-title":"Modeling complex decay profiles of hepatitis B virus","volume":"49","author":"H Dahari","year":"2009","journal-title":"Hepatology"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"7590","DOI":"10.1128\/JVI.01623-05","article-title":"Kinetics of influenza A virus infection in humans","volume":"80","author":"P Baccam","year":"2006","journal-title":"J Virol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jtbi.2008.05.031","article-title":"Modeling amantadine treatment of influenza A in vitro","volume":"254","author":"CA Beauchemin","year":"2008","journal-title":"J Theor Biol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jhep.2010.03.019","article-title":"Pharmacodynamics of PEG-IFN-<italic>\u03b1<\/italic>-2a in HIV\/HCV co-infected patients: Implications for treatment outcomes","volume":"53","author":"H Dahari","year":"2010","journal-title":"J Hepatol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/QAD.0b013e3283471d53","article-title":"Twice-weekly pegylated interferon-<italic>\u03b1<\/italic>-2a and ribavirin results in superior viral kinetics in HIV\/hepatitis C virus co-infected patients compared to standard therapy","volume":"25","author":"AA Murphy","year":"2011","journal-title":"AIDS"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jtbi.2003.09.002","article-title":"Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokineticsand intracellular delay","volume":"226","author":"NM Dixit","year":"2004","journal-title":"J Theor Biol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.biocel.2004.02.028","article-title":"Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors","volume":"36","author":"V Goldschmidt","year":"2004","journal-title":"Int J Biochem Cell Biol"}],"container-title":["PLoS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pcbi.1003769","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T19:57:08Z","timestamp":1689451028000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1003769"}},"subtitle":[],"editor":[{"given":"Rustom","family":"Antia","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2014,8,7]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2014,8,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1003769","relation":{},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,7]]}}}